Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Medicine information OPTISON injection suspension
- Product code:
- W51612002
- Quantity:
- 5
- Indicated for:
- diagnostic imaging contrast enhancement
- Route of administration:
- injectable
- Substance:
- perflutren (contrast agent)
- ATC
- V08DA01 — Various | Ultrasound contrast media
Perflutren is a contrast agent used in ultrasound imaging to enhance the visualization of cardiac and vascular structures. It contains gas microbubbles that reflect ultrasound waves, providing clearer and more detailed images.
The medication is administered intravenously under the supervision of a specialist during the imaging procedure. It is important to inform your doctor about any allergies or pre-existing conditions before administration.
Side effects may include nausea, headache, dizziness, or, in rare cases, severe allergic reactions such as anaphylaxis.
Patients should inform their doctor about any other medications being used or cardiovascular conditions to ensure the safe use of perflutren.
The medication is administered intravenously under the supervision of a specialist during the imaging procedure. It is important to inform your doctor about any allergies or pre-existing conditions before administration.
Side effects may include nausea, headache, dizziness, or, in rare cases, severe allergic reactions such as anaphylaxis.
Patients should inform their doctor about any other medications being used or cardiovascular conditions to ensure the safe use of perflutren.
General data about OPTISON
- Substance:
- perflutren
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W51612002
- Pharmaceutical form:
- injection suspension
- Quantity:
- 5
- Product type:
- Original
- Prescription status:
- S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Pharmaceutical forms available for perflutren
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
- Added to database:
- 01/08/2008
- Source record updated:
- 27/06/2022
Warnings:
Additional monitoring
This medicine is subject to additional monitoring.